Active	Status	Sponsor type	Region	Phase	Filter
17 Active 3 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ramos, Carlos
Neptuno, NCT04784559 / 2020-005951-19: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection	Terminated	3	205	Europe, RoW	Plitidepsin, Dexamethasone, Remdesivir, Favipiravir	PharmaMar	COVID-19 Infection	03/23	03/23
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD	Recruiting	2	156	US	MHS-1031, Panosyl-isomaltooligosaccharide, Placebo	Microbiome Health Sciences, VBHRC Virginia Catalyst	Gastroesophageal Reflux	07/25	07/25
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy	Active, not recruiting	1b	15	US	Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda	Tessa Therapeutics, Bristol-Myers Squibb	Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent	12/25	12/37
ANCHOR2, NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies	Recruiting	1	36	US	KUR-502, CD19.CAR-aNKT cells	Athenex, Inc.	NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL	12/23	12/24
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)